文献速递免疫规划卫生政策与健康促进

COVID-19大流行背景下用于疫苗有效性估计的检测阴性设计:一项系统方法学综述

Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology review.
PubMed 文献 · Vaccine · 2023-12-09

该研究系统检索四个生物医学数据库,纳入2020年1月1日至2022年1月25日发表的35项使用检测阴性设计(TND)估计COVID-19疫苗有效性的原创研究。多数研究来自北美(16项)并针对普通人群(28项),仅半数研究病例与对照采用相同纳入标准,部分研究报告了潜在未测量混杂、当前SARS-CoV-2感染错分和选择偏倚等局限性。作者认为COVID-19大流行期间TND的应用与已验证设计存在潜在有意义的偏离。

要点

  • 共纳入35项使用检测阴性设计估计COVID-19疫苗有效性的原创研究。
  • 多数研究来自北美(16项)并针对普通人群(28项)。
  • 仅半数研究病例与对照采用相同纳入标准,部分研究未考虑或未说明症状。

核心结论

  • 作者观察到COVID-19大流行期间检测阴性设计的应用与已验证设计存在潜在有意义的偏离。

研究设计与样本

  • 系统综述,检索四个生物医学数据库,检索时限为2020年1月1日至2022年1月25日,纳入使用检测阴性设计估计COVID-19疫苗有效性且基于SARS-CoV-2实验室检测结果评估病例和对照的原创文章。
  • 共识别96项研究,其中35项符合既定标准。

主要发现

  • 多数研究来自北美(16项研究)并针对普通人群(28项研究)。
  • 结局病例定义主要基于COVID-19样症状,但数篇论文未考虑或未说明症状。
  • 仅半数研究病例与对照具有相同纳入标准。
  • 多数研究依赖为其他(非评估)临床目的建立的行政或医院数据库。
  • 部分研究报告的局限性包括潜在未测量混杂(20项研究)、当前SARS-CoV-2感染错分(16项研究)和选择偏倚(10项研究)。

局限性

  • 部分研究报告了潜在未测量混杂(20项研究)作为局限性。
  • 部分研究报告了当前SARS-CoV-2感染错分(16项研究)作为局限性。
  • 部分研究报告了选择偏倚(10项研究)作为局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: During the height of the global COVID-19 pandemic, the test-negative design (TND) was extensively used in many countries to evaluate COVID-19 vaccine effectiveness (VE). Typically, the TND involves the recruitment of care-seeking individuals who meet a common clinical case definition. All participants are then tested for an infection of interest. OBJECTIVES: To review and describe the variation in TND methodology, and disclosure of potential biases, as applied to the evaluation of COVID-19 VE during the early vaccination phase of the pandemic. METHODS: We conducted a systematic review by searching four biomedical databases using defined keywords to identify peer-reviewed articles published between January 1, 2020, and January 25, 2022. We included only original articles that employed a TND to estimate VE of COVID-19 vaccines in which cases and controls were evaluated based on SARS-CoV-2 laboratory test results. RESULTS: We identified 96 studies, 35 of which met the defined criteria. Most studies were from North America (16 studies) and targeted the general population (28 studies). Outcome case definitions were based primarily on COVID-19-like symptoms; however, several papers did not consider or specify symptoms. Cases and controls had the same inclusion criteria in only half of the studies. Most studies relied upon administrative or hospital databases assembled for a different (non-evaluation) clinical purpose. Potential unmeasured confounding (20 studies), misclassification of current SARS-CoV-2 infection (16 studies) and selection bias (10 studies) were disclosed as limitations by some studies. CONCLUSION: We observed potentially meaningful deviations from the validated design in the application of the TND during the COVID-19 pandemic.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mésidor M, Liu Y, Talbot D, et al. Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology review. Vaccine. 2023. PMID: 38072756. doi:10.1016/j.vaccine.2023.12.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。